AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ARVN · NASDAQ · Biotechnology

Arvinas (ARVN)

Develops PROTAC degraders around VEPPANU and clinical oncology, neurology, and neuromuscular programs.

$8.42

vs last close−0.09 (−1.06%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	35	−43	25	77	102	59	189	22	42	10	16	250
Cost of revenue	2	2	2	2	0	0	0	0	0	1	1	9
Gross profit	33	−45	24	75	102	59	189	22	42	8	15	241
	107	121	107	123	163	117	117	94	86	80	77	77
Research & development	86	95	84	94	87	83	91	69	65	61	60	53
	21	25	23	30	76	34	27	25	22	22	17	24
Selling & marketing	0	−2	−2	−2	0	0	0	0	0	0	−2	0
General & administrative	0	27	24	31	76	34	27	25	22	22	19	24
Other expenses	0	0	0	0	0	0	0	0	−1	−4	0	0
Operating income	−74	−165	−83	−49	−60	−58	71	−72	−44	−72	−63	164
	10	12	14	14	12	13	12	10	9	5	5	6
Interest income	10	12	14	14	14	13	12	10	9	9	6	6
Other non-operating income	−10	−12	−14	−14	−12	−13	−12	−10	−9	−5	−5	6
Income before tax	−64	−153	−69	−35	−49	−46	83	−62	−35	−67	−58	170
Income tax expense	0	2	0	0	1	0	0	0	0	0	0	0
Net income from continuing operations	−64	−155	−69	−35	−49	−45	83	−61	−35	−67	−58	169
Net income	−64	−155	−69	−35	−49	−45	83	−61	−35	−67	−58	169
EPS, basic	−$1.18	−$2.53	−$0.97	−$0.49	−$0.68	−$0.63	$1.14	−$0.84	−$0.48	−$1.04	−$0.90	$2.61
EPS, diluted	−$1.18	−$2.53	−$0.97	−$0.49	−$0.68	−$0.63	$1.14	−$0.84	−$0.48	−$1.04	−$0.90	$2.58
Weighted average shares, basic	54	61	72	72	72	72	73	73	73	65	64	65
Weighted average shares, diluted	54	61	72	72	72	72	73	73	73	65	64	66
EBITDA	−62	−152	−68	−33	−48	−44	84	−60	−34	−66	−56	159
Depreciation & amortization	2	2	2	2	1	2	1	1	1	1	1	1
EBIT	−64	−153	−69	−35	−49	−46	83	−62	−35	−67	−58	159